SlideShare une entreprise Scribd logo
1  sur  40
Biological responses to tumor
hypoxia and their potential as
     therapeutic targets
       Brad Wouters



        This course is funded with the support of the METOXIA project
                          under the FP7 Programme.
Learning Objectives

Understand the importance of hypoxia to phenotypic
diversity in tumours

Identify mechanisms that promote hypoxia tolerance in
tumours

Understand why mTOR regulation by hypoxia is
important

Understand why UPR signaling during hypoxia is
important
                  This course is funded with the support of the METOXIA project
                                    under the FP7 Programme.
Phenotypic diversity exists within tumors
Genetic, epigenetic,
microenvironmental



Cellular ‘individuality’


Therapy ‘escape’

Therapies are not
equally effective
against all tumor
cells
Tumor hypoxia influences cancer biology


Gene expression


Cell phenotype
• Cell signaling
• Proliferation
• Metabolism
• Metastasis
• Angiogenesis
• DNA Repair,
• Stem cells
• Treatment resistance
Heterogeneity in Oxygenation



Amount                                                 Severity




Distribution   Photos courtesy of Bert van der Kogel
                                                         Time
The microenvironment is patient specific




  Cancer genetics influence the microenvironment
•   Metabolism
  Genes                   •   Angiogenesis
                          •   Genetic Instability
              Phenotype   •   Growth/proliferation
                          •   Metastasis
                          •   Stemness?
Environment
Hypoxia is a stable phenotype of pancreatic
cancers associated with aggressive disease




                        Chang and Hedley, 2011,Cancer Research
Hypoxia varies widely amongst patients
     Hypoxic fraction in head and neck cancer




                                                Hypoxic fraction ranges
                                                from 0-100%
Hypoxia predicts for poor outcome
                    397 head and neck patients – 7
                    centers Nordsmark M et al, Radiother
                    Oncol. 2005
Hypoxia and Treatment Outcome
Cervix cancer – hypoxia predicts for overall survival
     Disease-free survival             Metastasis




                                                Hypoxic
                        Hypoxic
PSA Failure-Free Rate by Tumor Hypoxia
                                          All Patients (n=247)             Bulk Patients (n=144)
                                1.0
Biochemical failure free rate




                                0.9


                                0.8       p=0.03                           p=0.009

                                0.7
                                          Oxic (HP10=20%)                  Oxic (HP10=20%)
                                          Hypoxic (HP10=80%)               Hypoxic (HP10=80%)
                                0.6
                                      0            20        40   60   0             20        40                 60
                                                   Time (month)                      Time (month)



                                                                                      Milosevic et al, in press
What determines tumour hypoxia?
1) Selection for hypoxia tolerant cells




                           Graeber TG et al. Nature 379(6560): 88-91, 1996
Hypoxia and Selection – The case of p53




       Hypoxia
Hypoxia-mediated mutation selection




                        Graeber TG et al. Nature 379(6560): 88-91, 1996
2) Hypoxia Initiates Adaptive Responses




                          Wouters and Koritzinsky, Nature Reviews Cancer 2008
mTOR is a central metabolic regulator that
   responds to environmental signals




       Hypoxia



                        Metabolism
                     Protein synthesis
                 Cell growth/proliferation
mTOR inhibition in hypoxic tumor areas




                           Hedley et al, unpublished
Hypoxia suppresses mTOR and metabolism
            PTEN




            Metabolism
            Growth
            Proliferation
            Survival


                            Koritzinsky et al, EMBO, 2006
mTOR inhibition promotes hypoxia
             tolerance in vivo
                              Measure hypoxia            Measure hypoxia
               Inject cells

                                 +/- Dox
     4E   4E
OE




                                                Rouschop et al, 2011
mTOR inhibition during hypoxia
                             promotes therapy resistance
                                                                                                                                  IR response
                                                       Inject cells

                                                                                                              +/- Dox

     4E                         4E
OE



                            4                                                                    4




                            3                                                                    3
     Relative tumour size




                                                                          Relative tumour size
                                15Gy                                                                 15Gy

                            2                                                                    2




                            1                        PCDNA5                                      1
                                                                                                                                     eIF4E

                                         Dox                                                                  Dox
                            0                                                                    0
                                -7   0   7   14 21 28 35 42 49 56 63 70                              -7   0    7   14 21 28 35 42 49 56 63 70
                                              Days                                                                        Days
                                                                                                                                  Rouschop et al, 2011
Hypoxia activates all 3 arms of the UPR



                   Anoxia
   [hrs]   0   1   2   4    8
eIF2α-P
                                                                                   Anoxia
eIF2α
                                                                    [hrs]       0 1 2 4 6
                                                                            *
                                                                   ATF-6

                                          Anoxia
                                [hrs]   0 .5   2 6
                                                     XBP-1u
                                                     XBP-1s




                                                      Wouters and Koritzinsky, Nature Reviews Cancer 2008
Targeting the UPR sensitizes cells to hypoxia
Inject cells

                    +/- Dox




               DN




               OE
Targeting the UPR improves treatment
                                                                                   IR
         Inject cells

                                                                  +/- Dox




                                         4

DN                                       3
                                             15Gy
                   Relative tumor size




                                         2


                                         1


                                         0
                                                    Dox
                                             -7 0   7 14 21 28 35 42 49 56 63 70

                                                            Days
Why is UPR signaling important ?



Phenotype                 Tolerance

 Metastasis               Autophagy
 LAMP3                    LC3B, ATG5



    pH control        ROS, redox
    CA9               Glutathione biosynthesis
                      Amino acid biosynthesis
Hypoxia inhibits translation through PERK




                         HeLa
                 C   1   2      4   8   C DTT
                                                    eIF2 - P

                                                    actin

                                                Koumenis et al., MCB, 2002
Hypoxia inhibits mRNA translation
            transcription         translation
      DNA                   RNA                 Protein


                Hypoxia             Hypoxia




      Hypoxia
Hypoxia inhibits overall protein synthesis

                     Hypoxia




   Preserve energy             Change which genes
   (ATP)                       are made into proteins
PERK/UPR signaling protects against ROS
    induced by fluctuating hypoxia
The UPR regulates CA9




van den Beucken and Wouters, unpublished data
The UPR Enables Autophagy




1 – Provide energy and nutrients during starvation
2 – Remove damaged organelles and protein aggregates

          Both processes are cytoprotective
Autophagy is activated in hypoxic
                  tumors
                                 N




SCCNij172                      Lc3b/pimo/vessels
The UPR induces LC3B via ATF4
LC3 is turned over during
        autophagy




                  Geng and Klionsky, EMBO reports, 2008
LC3B protein is lost in UPR deficient cells

               HCT116                             U373


                        Wildtype                  Wildtype
LC3B protein




                                   LC3B protein
               PERK defective                     PERK defective
Hypoxia and the UPR stimulate autophagy
                              Energy
                              Removal of toxins




                        Rouschop, JCI, 2011
PERK regulates energy metabolism
Inhibition of protein
synthesis

                   Bioenergetic
             homeostasis and protection
                  against ROS




         Metabolism
Summary

• Hypoxia causes phenotypic diversity in tumours
• Hypoxia in patients is variable and determined
  by mechanisms that influence hypoxia tolerance
• Hypoxia tolerance is influenced by mTOR and
  UPR regulation
• UPR influences hypoxia tolerance through
  multiple mechanisms
  – ROS, pH, autophagy, metabolism

Contenu connexe

Tendances

Hypoxic cell sensitisers
Hypoxic cell sensitisersHypoxic cell sensitisers
Hypoxic cell sensitisers
Bharti Devnani
 
Antineoplastic agent chemotherapeutic treatment to fight against cancer
Antineoplastic agent chemotherapeutic treatment to fight against cancerAntineoplastic agent chemotherapeutic treatment to fight against cancer
Antineoplastic agent chemotherapeutic treatment to fight against cancer
Alexander Decker
 
Antibiotic dosing in msof.full
Antibiotic dosing in msof.fullAntibiotic dosing in msof.full
Antibiotic dosing in msof.full
Antal Oana
 
radio protectors
radio protectorsradio protectors
radio protectors
Divya Singh
 
The flavonoid quercetin transientyly inhibits the activity of taxol and nocod...
The flavonoid quercetin transientyly inhibits the activity of taxol and nocod...The flavonoid quercetin transientyly inhibits the activity of taxol and nocod...
The flavonoid quercetin transientyly inhibits the activity of taxol and nocod...
Tiensae Teshome
 
Mathur A PLOS ONE 2014
Mathur A PLOS ONE 2014Mathur A PLOS ONE 2014
Mathur A PLOS ONE 2014
Aditi Mathur
 

Tendances (20)

Radiation response modifiers
Radiation response modifiersRadiation response modifiers
Radiation response modifiers
 
Growth inhibitory effects of vitamin k2 (menaquinones mk4) on bladder carcin...
Growth inhibitory effects of vitamin k2 (menaquinones  mk4) on bladder carcin...Growth inhibitory effects of vitamin k2 (menaquinones  mk4) on bladder carcin...
Growth inhibitory effects of vitamin k2 (menaquinones mk4) on bladder carcin...
 
VIRAL AND NON VIRAL GENE TRANSFER
VIRAL AND NON VIRAL GENE TRANSFER VIRAL AND NON VIRAL GENE TRANSFER
VIRAL AND NON VIRAL GENE TRANSFER
 
Hypoxic cell sensitisers
Hypoxic cell sensitisersHypoxic cell sensitisers
Hypoxic cell sensitisers
 
Crimson Publishers-Nanoparticle (NP) Delivery of Chemotherapy Drugs to Prost...
Crimson Publishers-Nanoparticle (NP) Delivery of Chemotherapy  Drugs to Prost...Crimson Publishers-Nanoparticle (NP) Delivery of Chemotherapy  Drugs to Prost...
Crimson Publishers-Nanoparticle (NP) Delivery of Chemotherapy Drugs to Prost...
 
Antineoplastic agent chemotherapeutic treatment to fight against cancer
Antineoplastic agent chemotherapeutic treatment to fight against cancerAntineoplastic agent chemotherapeutic treatment to fight against cancer
Antineoplastic agent chemotherapeutic treatment to fight against cancer
 
Polymer therapeutics: an smart drug delivary system
Polymer therapeutics: an smart drug delivary systemPolymer therapeutics: an smart drug delivary system
Polymer therapeutics: an smart drug delivary system
 
Antibiotic dosing in msof.full
Antibiotic dosing in msof.fullAntibiotic dosing in msof.full
Antibiotic dosing in msof.full
 
radio protectors
radio protectorsradio protectors
radio protectors
 
Nanotechnology based drug delivery systems for the treatment of tuberculosis
Nanotechnology based drug delivery systems for the treatment of tuberculosisNanotechnology based drug delivery systems for the treatment of tuberculosis
Nanotechnology based drug delivery systems for the treatment of tuberculosis
 
Community Oncology Clinical Debates: Advanced Melanoma
Community Oncology Clinical Debates: Advanced MelanomaCommunity Oncology Clinical Debates: Advanced Melanoma
Community Oncology Clinical Debates: Advanced Melanoma
 
The flavonoid quercetin transientyly inhibits the activity of taxol and nocod...
The flavonoid quercetin transientyly inhibits the activity of taxol and nocod...The flavonoid quercetin transientyly inhibits the activity of taxol and nocod...
The flavonoid quercetin transientyly inhibits the activity of taxol and nocod...
 
Disruption of focal adhesion kinase and p53 interaction with small molecule c...
Disruption of focal adhesion kinase and p53 interaction with small molecule c...Disruption of focal adhesion kinase and p53 interaction with small molecule c...
Disruption of focal adhesion kinase and p53 interaction with small molecule c...
 
Radioprotectors 130719061711-phpapp02
Radioprotectors 130719061711-phpapp02Radioprotectors 130719061711-phpapp02
Radioprotectors 130719061711-phpapp02
 
cancer
cancercancer
cancer
 
nature19764
nature19764nature19764
nature19764
 
RATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical data
RATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical dataRATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical data
RATIONAL COMBINATION IMMUNOTHERAPY: The best of ASCO16 clinical data
 
Radioprotectors
RadioprotectorsRadioprotectors
Radioprotectors
 
Mathur A PLOS ONE 2014
Mathur A PLOS ONE 2014Mathur A PLOS ONE 2014
Mathur A PLOS ONE 2014
 
Gene therapy types advantags disadvantages
Gene therapy types advantags disadvantagesGene therapy types advantags disadvantages
Gene therapy types advantags disadvantages
 

En vedette

thyriod gland imaging part 5 (molecular imaging nuclear imaging spect) Dr Ahm...
thyriod gland imaging part 5 (molecular imaging nuclear imaging spect) Dr Ahm...thyriod gland imaging part 5 (molecular imaging nuclear imaging spect) Dr Ahm...
thyriod gland imaging part 5 (molecular imaging nuclear imaging spect) Dr Ahm...
AHMED ESAWY
 
Cancer metabolism lecture, Hood College (10-18-10)
Cancer metabolism lecture, Hood College (10-18-10)Cancer metabolism lecture, Hood College (10-18-10)
Cancer metabolism lecture, Hood College (10-18-10)
James Gould, PhD
 

En vedette (7)

Clinical Imaging Hypoxia
Clinical Imaging HypoxiaClinical Imaging Hypoxia
Clinical Imaging Hypoxia
 
thyriod gland imaging part 5 (molecular imaging nuclear imaging spect) Dr Ahm...
thyriod gland imaging part 5 (molecular imaging nuclear imaging spect) Dr Ahm...thyriod gland imaging part 5 (molecular imaging nuclear imaging spect) Dr Ahm...
thyriod gland imaging part 5 (molecular imaging nuclear imaging spect) Dr Ahm...
 
Clinical Trials for Brain Tumor Patients
Clinical Trials for Brain Tumor PatientsClinical Trials for Brain Tumor Patients
Clinical Trials for Brain Tumor Patients
 
Multiplex energy metabolism
Multiplex energy metabolismMultiplex energy metabolism
Multiplex energy metabolism
 
Molecular Imaging
Molecular ImagingMolecular Imaging
Molecular Imaging
 
Metabolic Immunology
Metabolic ImmunologyMetabolic Immunology
Metabolic Immunology
 
Cancer metabolism lecture, Hood College (10-18-10)
Cancer metabolism lecture, Hood College (10-18-10)Cancer metabolism lecture, Hood College (10-18-10)
Cancer metabolism lecture, Hood College (10-18-10)
 

Similaire à Biological responses to tumor hypoxia & their potential as therapeutic targets

Benhamou co infection
Benhamou    co infectionBenhamou    co infection
Benhamou co infection
odeckmyn
 
Radiation therapy for head and neck cancer by Brian O'Sullivan
Radiation therapy for head and neck cancer by Brian O'SullivanRadiation therapy for head and neck cancer by Brian O'Sullivan
Radiation therapy for head and neck cancer by Brian O'Sullivan
Eurasian Federation of Oncology
 
Novel therapies in hcc
Novel therapies in hccNovel therapies in hcc
Novel therapies in hcc
James Hilbert
 
Larynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Larynx Preservation: the Nonsurgical Approach by Jan B. VermorkenLarynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Larynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Eurasian Federation of Oncology
 
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and DiseasesMETOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
MAASTRO clinic
 
Osteros Biomedica presentation for Adam Smith Conference 2012
Osteros Biomedica presentation for Adam Smith Conference 2012Osteros Biomedica presentation for Adam Smith Conference 2012
Osteros Biomedica presentation for Adam Smith Conference 2012
MaxwellBiotech
 
02-pre-CDR-Radiobiology-Motivation-March-2020.pptx
02-pre-CDR-Radiobiology-Motivation-March-2020.pptx02-pre-CDR-Radiobiology-Motivation-March-2020.pptx
02-pre-CDR-Radiobiology-Motivation-March-2020.pptx
Nishant835443
 

Similaire à Biological responses to tumor hypoxia & their potential as therapeutic targets (20)

Research progress by dr. Yuyun Rindiastuti
Research progress by dr. Yuyun RindiastutiResearch progress by dr. Yuyun Rindiastuti
Research progress by dr. Yuyun Rindiastuti
 
Mechanism of resistance to target therapy
Mechanism of resistance to target therapyMechanism of resistance to target therapy
Mechanism of resistance to target therapy
 
Michael Buschmann_Nanomedecine
Michael Buschmann_NanomedecineMichael Buschmann_Nanomedecine
Michael Buschmann_Nanomedecine
 
Benhamou co infection
Benhamou    co infectionBenhamou    co infection
Benhamou co infection
 
Opioid replacement therapy.pptx
Opioid replacement therapy.pptxOpioid replacement therapy.pptx
Opioid replacement therapy.pptx
 
Investigating the Mechanism of Antioxidant MnTE-2-PyP as SOD1 Mimetic in Pros...
Investigating the Mechanism of Antioxidant MnTE-2-PyP as SOD1 Mimetic in Pros...Investigating the Mechanism of Antioxidant MnTE-2-PyP as SOD1 Mimetic in Pros...
Investigating the Mechanism of Antioxidant MnTE-2-PyP as SOD1 Mimetic in Pros...
 
A seminar report on the chemical frontiers of living matter seminar series - ...
A seminar report on the chemical frontiers of living matter seminar series - ...A seminar report on the chemical frontiers of living matter seminar series - ...
A seminar report on the chemical frontiers of living matter seminar series - ...
 
Matsunami et al., 2010 2nd
Matsunami et al., 2010 2ndMatsunami et al., 2010 2nd
Matsunami et al., 2010 2nd
 
As process development and manufacturing (cmc) for biologics development-an o...
As process development and manufacturing (cmc) for biologics development-an o...As process development and manufacturing (cmc) for biologics development-an o...
As process development and manufacturing (cmc) for biologics development-an o...
 
Radiation therapy for head and neck cancer by Brian O'Sullivan
Radiation therapy for head and neck cancer by Brian O'SullivanRadiation therapy for head and neck cancer by Brian O'Sullivan
Radiation therapy for head and neck cancer by Brian O'Sullivan
 
Neuropharmacology: Nicotine
Neuropharmacology: NicotineNeuropharmacology: Nicotine
Neuropharmacology: Nicotine
 
Novel therapies in hcc
Novel therapies in hccNovel therapies in hcc
Novel therapies in hcc
 
SummerPoster
SummerPosterSummerPoster
SummerPoster
 
Larynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Larynx Preservation: the Nonsurgical Approach by Jan B. VermorkenLarynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
Larynx Preservation: the Nonsurgical Approach by Jan B. Vermorken
 
Introduction to Oligonucleotides and vaccines
Introduction to Oligonucleotides and vaccinesIntroduction to Oligonucleotides and vaccines
Introduction to Oligonucleotides and vaccines
 
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
Development of Novel Targeted Drugs: Which Target? by Eric RaymondDevelopment of Novel Targeted Drugs: Which Target? by Eric Raymond
Development of Novel Targeted Drugs: Which Target? by Eric Raymond
 
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and DiseasesMETOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
METOXIA Framework and Hypoxia and Acidosis in Human Physiology and Diseases
 
Osteros Biomedica presentation for Adam Smith Conference 2012
Osteros Biomedica presentation for Adam Smith Conference 2012Osteros Biomedica presentation for Adam Smith Conference 2012
Osteros Biomedica presentation for Adam Smith Conference 2012
 
02-pre-CDR-Radiobiology-Motivation-March-2020.pptx
02-pre-CDR-Radiobiology-Motivation-March-2020.pptx02-pre-CDR-Radiobiology-Motivation-March-2020.pptx
02-pre-CDR-Radiobiology-Motivation-March-2020.pptx
 
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
2011 10 26_quantitative_cell_biology_molecular_profiling_v_twitter
 

Plus de MAASTRO clinic

e-Learning What, Why & How
e-Learning What, Why & Howe-Learning What, Why & How
e-Learning What, Why & How
MAASTRO clinic
 
ARTFORCE - Radiation Protection Zr-cetuximab
ARTFORCE - Radiation Protection Zr-cetuximabARTFORCE - Radiation Protection Zr-cetuximab
ARTFORCE - Radiation Protection Zr-cetuximab
MAASTRO clinic
 
Knowledge Engineering in Oncology
Knowledge Engineering in OncologyKnowledge Engineering in Oncology
Knowledge Engineering in Oncology
MAASTRO clinic
 
General information course 2.3
General information course 2.3General information course 2.3
General information course 2.3
MAASTRO clinic
 
HIF in cell Biology & Physiology
HIF in cell Biology & PhysiologyHIF in cell Biology & Physiology
HIF in cell Biology & Physiology
MAASTRO clinic
 

Plus de MAASTRO clinic (14)

Maastro corporate presentatie 2015
Maastro corporate presentatie 2015Maastro corporate presentatie 2015
Maastro corporate presentatie 2015
 
e-Learning What, Why & How
e-Learning What, Why & Howe-Learning What, Why & How
e-Learning What, Why & How
 
ARTFORCE - Radiation Protection Zr-cetuximab
ARTFORCE - Radiation Protection Zr-cetuximabARTFORCE - Radiation Protection Zr-cetuximab
ARTFORCE - Radiation Protection Zr-cetuximab
 
MAASTRO Knowledge Engineering: The Fun(ction) of Medical Physics in Cancer Care
MAASTRO Knowledge Engineering: The Fun(ction) of Medical Physics in Cancer CareMAASTRO Knowledge Engineering: The Fun(ction) of Medical Physics in Cancer Care
MAASTRO Knowledge Engineering: The Fun(ction) of Medical Physics in Cancer Care
 
Multi-centric learning from medical data
Multi-centric learning from medical dataMulti-centric learning from medical data
Multi-centric learning from medical data
 
Knowledge Engineering in Oncology
Knowledge Engineering in OncologyKnowledge Engineering in Oncology
Knowledge Engineering in Oncology
 
General information course 2.3
General information course 2.3General information course 2.3
General information course 2.3
 
Carbonic Anhydrase IX: regulation and role in cancer
Carbonic Anhydrase IX: regulation and role in cancerCarbonic Anhydrase IX: regulation and role in cancer
Carbonic Anhydrase IX: regulation and role in cancer
 
Measuring of biological parameters of the tumor microenvironment – advantages...
Measuring of biological parameters of the tumor microenvironment – advantages...Measuring of biological parameters of the tumor microenvironment – advantages...
Measuring of biological parameters of the tumor microenvironment – advantages...
 
Principles of 3D Fitting of Molecules
Principles of 3D Fitting of MoleculesPrinciples of 3D Fitting of Molecules
Principles of 3D Fitting of Molecules
 
Hypoxia as a target for personalized medicine
Hypoxia as a target for personalized medicineHypoxia as a target for personalized medicine
Hypoxia as a target for personalized medicine
 
Global & local oxygen control in in vitro systems
Global & local oxygen control in in vitro systemsGlobal & local oxygen control in in vitro systems
Global & local oxygen control in in vitro systems
 
HIF in cell Biology & Physiology
HIF in cell Biology & PhysiologyHIF in cell Biology & Physiology
HIF in cell Biology & Physiology
 
Epigenetic Mechanisms Regulating the Cellular Response to Hypoxia
Epigenetic Mechanisms Regulating the Cellular Response to HypoxiaEpigenetic Mechanisms Regulating the Cellular Response to Hypoxia
Epigenetic Mechanisms Regulating the Cellular Response to Hypoxia
 

Dernier

Dernier (20)

Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 

Biological responses to tumor hypoxia & their potential as therapeutic targets

  • 1. Biological responses to tumor hypoxia and their potential as therapeutic targets Brad Wouters This course is funded with the support of the METOXIA project under the FP7 Programme.
  • 2. Learning Objectives Understand the importance of hypoxia to phenotypic diversity in tumours Identify mechanisms that promote hypoxia tolerance in tumours Understand why mTOR regulation by hypoxia is important Understand why UPR signaling during hypoxia is important This course is funded with the support of the METOXIA project under the FP7 Programme.
  • 3. Phenotypic diversity exists within tumors Genetic, epigenetic, microenvironmental Cellular ‘individuality’ Therapy ‘escape’ Therapies are not equally effective against all tumor cells
  • 4. Tumor hypoxia influences cancer biology Gene expression Cell phenotype • Cell signaling • Proliferation • Metabolism • Metastasis • Angiogenesis • DNA Repair, • Stem cells • Treatment resistance
  • 5. Heterogeneity in Oxygenation Amount Severity Distribution Photos courtesy of Bert van der Kogel Time
  • 6. The microenvironment is patient specific Cancer genetics influence the microenvironment
  • 7. Metabolism Genes • Angiogenesis • Genetic Instability Phenotype • Growth/proliferation • Metastasis • Stemness? Environment
  • 8. Hypoxia is a stable phenotype of pancreatic cancers associated with aggressive disease Chang and Hedley, 2011,Cancer Research
  • 9. Hypoxia varies widely amongst patients Hypoxic fraction in head and neck cancer Hypoxic fraction ranges from 0-100%
  • 10. Hypoxia predicts for poor outcome 397 head and neck patients – 7 centers Nordsmark M et al, Radiother Oncol. 2005
  • 11. Hypoxia and Treatment Outcome Cervix cancer – hypoxia predicts for overall survival Disease-free survival Metastasis Hypoxic Hypoxic
  • 12. PSA Failure-Free Rate by Tumor Hypoxia All Patients (n=247) Bulk Patients (n=144) 1.0 Biochemical failure free rate 0.9 0.8 p=0.03 p=0.009 0.7 Oxic (HP10=20%) Oxic (HP10=20%) Hypoxic (HP10=80%) Hypoxic (HP10=80%) 0.6 0 20 40 60 0 20 40 60 Time (month) Time (month) Milosevic et al, in press
  • 14. 1) Selection for hypoxia tolerant cells Graeber TG et al. Nature 379(6560): 88-91, 1996
  • 15. Hypoxia and Selection – The case of p53 Hypoxia
  • 16. Hypoxia-mediated mutation selection Graeber TG et al. Nature 379(6560): 88-91, 1996
  • 17. 2) Hypoxia Initiates Adaptive Responses Wouters and Koritzinsky, Nature Reviews Cancer 2008
  • 18. mTOR is a central metabolic regulator that responds to environmental signals Hypoxia Metabolism Protein synthesis Cell growth/proliferation
  • 19. mTOR inhibition in hypoxic tumor areas Hedley et al, unpublished
  • 20. Hypoxia suppresses mTOR and metabolism PTEN Metabolism Growth Proliferation Survival Koritzinsky et al, EMBO, 2006
  • 21. mTOR inhibition promotes hypoxia tolerance in vivo Measure hypoxia Measure hypoxia Inject cells +/- Dox 4E 4E OE Rouschop et al, 2011
  • 22. mTOR inhibition during hypoxia promotes therapy resistance IR response Inject cells +/- Dox 4E 4E OE 4 4 3 3 Relative tumour size Relative tumour size 15Gy 15Gy 2 2 1 PCDNA5 1 eIF4E Dox Dox 0 0 -7 0 7 14 21 28 35 42 49 56 63 70 -7 0 7 14 21 28 35 42 49 56 63 70 Days Days Rouschop et al, 2011
  • 23. Hypoxia activates all 3 arms of the UPR Anoxia [hrs] 0 1 2 4 8 eIF2α-P Anoxia eIF2α [hrs] 0 1 2 4 6 * ATF-6 Anoxia [hrs] 0 .5 2 6 XBP-1u XBP-1s Wouters and Koritzinsky, Nature Reviews Cancer 2008
  • 24. Targeting the UPR sensitizes cells to hypoxia Inject cells +/- Dox DN OE
  • 25. Targeting the UPR improves treatment IR Inject cells +/- Dox 4 DN 3 15Gy Relative tumor size 2 1 0 Dox -7 0 7 14 21 28 35 42 49 56 63 70 Days
  • 26. Why is UPR signaling important ? Phenotype Tolerance Metastasis Autophagy LAMP3 LC3B, ATG5 pH control ROS, redox CA9 Glutathione biosynthesis Amino acid biosynthesis
  • 27. Hypoxia inhibits translation through PERK HeLa C 1 2 4 8 C DTT eIF2 - P actin Koumenis et al., MCB, 2002
  • 28. Hypoxia inhibits mRNA translation transcription translation DNA RNA Protein Hypoxia Hypoxia Hypoxia
  • 29. Hypoxia inhibits overall protein synthesis Hypoxia Preserve energy Change which genes (ATP) are made into proteins
  • 30. PERK/UPR signaling protects against ROS induced by fluctuating hypoxia
  • 31. The UPR regulates CA9 van den Beucken and Wouters, unpublished data
  • 32. The UPR Enables Autophagy 1 – Provide energy and nutrients during starvation 2 – Remove damaged organelles and protein aggregates Both processes are cytoprotective
  • 33. Autophagy is activated in hypoxic tumors N SCCNij172 Lc3b/pimo/vessels
  • 34. The UPR induces LC3B via ATF4
  • 35. LC3 is turned over during autophagy Geng and Klionsky, EMBO reports, 2008
  • 36. LC3B protein is lost in UPR deficient cells HCT116 U373 Wildtype Wildtype LC3B protein LC3B protein PERK defective PERK defective
  • 37. Hypoxia and the UPR stimulate autophagy Energy Removal of toxins Rouschop, JCI, 2011
  • 38. PERK regulates energy metabolism
  • 39. Inhibition of protein synthesis Bioenergetic homeostasis and protection against ROS Metabolism
  • 40. Summary • Hypoxia causes phenotypic diversity in tumours • Hypoxia in patients is variable and determined by mechanisms that influence hypoxia tolerance • Hypoxia tolerance is influenced by mTOR and UPR regulation • UPR influences hypoxia tolerance through multiple mechanisms – ROS, pH, autophagy, metabolism

Notes de l'éditeur

  1. A key challenge for treating cancer effectively arises from phenotypic diversity within individual cancers. This is especially true when we are considering potentially curative therapies.
  2. The genetic and epigenetic changes in tumor cells can tell us a lot about the nature of tumors, but is not enough to fully understand them. This is because the tumor microenvironment plays a critical role on the behavior of tumors by regulating many phenotypes that we associate with cancer.
  3. Understanding the role and function of the genes and pathways altered in cancer requires us to consider them in context. There is evidence to suggest that genes/pathways are altered in cancer not only to facilitate cell autonomous functions (proliferation/survival) but also to influence their microenvironment. Simialrly, the genes that do provide cell autonmous advantages can have dramatic consequences for the micorenvironment. Eg apopotosis. Consequently the phenotype of both normal tissues, and tumors is a complex interaction between genes and their environment.
  4. Importance goes beyond therapy resistance
  5. Several key pathways have been recognized as important determinants of hypoxia tolerance, and thus the proportion of viable hypoxic cells in human tumors. These pathways are distinct, show unique dependencies on oxygen concentration, and influence many different downstream signalling pathways. However, a common theme that emerges from our current understanding is the ability of these pathways to transiently reprogram metabolism in a way that promotes energy homeostasis and cell survival.
  6. Ubiquitin like molecule that is turned over
  7. We are addressing this question – what is the importance of mTOR/4F regulation. We hypothesize that tumor cells maintain control over mTOR mediated translation to faciliate survival